Humacyte Names Vascular Surgeon Todd Rasmussen as Chief Surgical Officer for Symvess Rollout
Humacyte hired Todd E. Rasmussen, a vascular surgeon with 28-year Air Force and Mayo Clinic tenure, as Chief Surgical Officer to provide peer-to-peer support and clinical education. His role aims to optimize safe and effective Symvess® implantation as clinical adoption ramps up across U.S. and international markets.
1. Appointment Highlights
On May 12, 2026, Humacyte appointed Todd E. Rasmussen, M.D., as Chief Surgical Officer, integrating a distinguished vascular surgeon into its executive team. This move underscores the company’s focus on advancing clinical adoption of its bioengineered tissues, including Symvess®, at commercial scale.
2. Responsibilities and Role
In this capacity, Rasmussen will deliver peer-to-peer scientific support, lead medical education programs, and develop clinical support materials conforming to regulatory guidelines. His work is designed to ensure the safe, appropriate, and effective implantation of Humacyte’s products in both U.S. and international healthcare settings.
3. Professional Background
Rasmussen brings 28 years of experience from the U.S. Air Force—culminating in a Defense Superior Service Medal—and his tenure as a vascular surgery professor at Mayo Clinic. He has led Department of Defense research programs, authored over 350 peer-reviewed papers, and will continue his Mayo Clinic responsibilities alongside his Humacyte role.